



Our mission is to transform
the lives of patients through
high-precision cell therapy

About Orca Bio

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company's investigational therapies are designed to replace a patient's diseased blood and immune system with a new one, with the goal of improving outcomes with fewer toxicities than a conventional transplant.

Redefining Cell Therapy Through the Power of Precision

Conventional stem cell transplants can be life-saving for patients with blood cancers, but many still face serious complications, including relapse, infection and graft versus host disease (GVHD).

Orca Bio's high-precision platform analyzes and selects individual donor cells to create a personalized mixture of stem and immune cells. By engineering the composition of each product at the cellular level, the goal is to not only reset the immune system and treat the disease, but reduce treatment-related toxicity and mortality.

Orca-T® is Orca Bio's lead investigational allogeneic T-cell immunotherapy being evaluated for the treatment of hematological malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). Orca-T is currently under review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of July 6, 2026.

Manufacturing Excellence

Orca Bio has built a centralized, proprietary manufacturing platform designed to deliver high-precision cell therapies with efficiency and scale.

Each Orca Bio product is manufactured by a highly specialized team to exact cellular specifications to enable consistent production and rapid delivery. Orca Bio has demonstrated the ability to deliver product within 72 hours vein-to-vein, supporting the speed and reliability required for patients with urgent medical need.

Expanding the Future of High-Precision Cell Therapy

Orca Bio is advancing its next-generation pipeline to expand the potential of high-precision cell therapy across additional hematologic and immune-mediated diseases, with the ultimate goal of reaching more patients in need.



FAST FACTS

Year Founded
2016

Location
Menlo Park, CA
Headquarters

Sacramento, CA
Commercial and Clinical
Manufacturing Facilities

Employees
300+

Patients Treated in Clinical
Trials
Approx. 550



To learn more, visit orcabio.com

Disclaimer. Investigational New Drug, not approved in any jurisdiction.